Press Releases

Novan Adds Clinical Exposure and Safety Data to SB204 Acne Program

June 10, 2015

DURHAM, N.C. – Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that following topical application of SB204 there was no measurable systemic exposure in patients with acne vulgaris. 

Full Story

Novan Secures $50 Million Private Financing

March 30, 2015

DURHAM, N.C. - Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that it has secured $50 million in an oversubscribed private financing.  New investor Malin Corporation Plc. (ISEQ: MLC) functioned as the cornerstone investor along with strong participation from Novan’s existing private investors throughout the Research Triangle area of North Carolina.

Full Story

Novan Achieves Target Enrollment for Phase 2 Acne Study 

March 18, 2015

DURHAM, N.C. - Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that the Company has achieved target enrollment in its Phase 2b clinical study with SB204 for the treatment of acne vulgaris.  Acne is the most common skin disease in the United States, affecting more than 50 million people. 

Full Story

Novan Expands Leadership Team with Vice President of Regulatory Affairs

February 26, 2015

DURHAM, N.C. - Novan Therapeutics, a clinical stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that Kevin Barber, Ph.D., has been appointed to the newly created position of Vice President of Regulatory Affairs, effective immediately.  Dr. Barber will direct Novan’s regulatory strategy as the primary interface with the FDA and will report directly to Dr. Nathan Stasko, Novan’s President. 

Full Story

Close
Close